AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9216530
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream application followed by infiltration of 1% lidocaine
Trial: 2445118
Drug: Mexiletine 200
RxNorm normalized name: mexiletine 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine 200 mg t.i.d.
Trial: 2445118
Drug: Mexiletine perlongettes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine perlongettes 360 mg b.i.d.
Trial: 29526693
Drug: Commercial non-carbonated
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial non-carbonated LCS lemonade (330 ml) consumed with meals
Trial: 29526693
Drug: 660 ml
RxNorm normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660 ml LCS lemonade daily (habituation group)
Trial: 29526693
Drug: 660 ml
RxNorm normalized name: ALCOHOL 2660 mL in 3800 mL TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 660 ml water (control group)
Trial: 20623311
Drug: Joint lavage
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint lavage in combination with triamcinolone hexacetonide (TH) intra-articular injection
Trial: 20623311
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (TH) intra-articular injection
Trial: 20623311
Drug: Joint lavage
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint lavage in combination with TH
Trial: 18926392
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with SCA (group 2: 12 patients on chronic transfusion therapy)
Trial: 12837672
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium (250 mg/day - 1,500 mg/day; mean: 851 mg/day)
Trial: 10784625
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine intensification
Trial: 9309990
Drug: Methacholine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine inhalation
Trial: 3159530
Drug: Ciprofloxacin 25
RxNorm normalized name: ciprofloxacin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 25 mg
Trial: 3159530
Drug: Ciprofloxacin 50
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 50 mg
Trial: 3159530
Drug: Ciprofloxacin 75
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 75 mg
Trial: 31658113
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nicotine lozenge
Trial: 27430374
Drug: Artesunate-mefloquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate-mefloquine (25 mg artesunate and 55 mg mefloquine) once a day for 3 days
Trial: 27430374
Drug: Artemether-lumefantrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (20 mg artemether and 120 mg lumefantrine) twice a day for 3 days
Trial: 20421332
Drug: rhGH (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGH (both doses)
Trial: 19077190
Drug: Exercise on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise on Prescription program with weekly exercise sessions for 20 weeks
Trial: 12828743
Drug: Synchronous balneo-phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synchronous balneo-phototherapy (simultaneous application of narrowband ultraviolet B and bathing in 10% Dead Sea salt solution)
Trial: 10494182
Drug: Various methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various methods of immunotherapy (interleukin‐2, Linomid, mixed hemopoietic cell transplantation)
Trial: 2069877
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose regimen of tamoxifen (160 mg for two days followed by 40 mg/day)
Trial: 2069877
Drug: Conventional schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional schedule of tamoxifen (40 mg/day)
Trial: 31923762
Drug: TRAIL/Apo2L monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAIL/Apo2L monotherapy
Trial: 23667467
Drug: Estrogen combined
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen combined with medroxyprogesterone acetate therapy
Trial: 19894006
Drug: Functional magnetic
RxNorm normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Functional magnetic stimulation (20-min stimulation session twice daily for 3 weeks)
Trial: 15530138
Drug: Induction morphine
RxNorm normalized name: morphine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction morphine
Trial: 14665865
Drug: 19 intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 1 year (group 1)
Trial: 14665865
Drug: 9 intravesical
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 intravesical instillations of epirubicin (30 mg/30 ml in normal saline) over 3 months (group 2)
Trial: 10403729
Drug: Empirical eradication
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Empirical eradication therapy
Trial: 7029236
Drug: Subunit vaccine
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit vaccine (SV)
Trial: 10438047
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three vaccines
Trial: 30335525
Drug: in vivo
RxNorm normalized name: IMAGING AGENTS (IN VIVO) RADIOPHARMACEUTICALS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in vivo exposure therapy (iVET)
Trial: 30335525
Drug: virtual reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: virtual reality exposure therapy (VRET)
Trial: 30335525
Drug: augmented reality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: augmented reality exposure therapy (ARET)
Trial: 19752552
Drug: terutroban 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terutroban 10 mg/day
Trial: 19752552
Drug: terutroban 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terutroban 10 mg/day + aspirin 300 mg/day
Trial: 19752552
Drug: clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel 75 mg/day + aspirin 300 mg/day
Trial: 19752552
Drug: aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 300 mg/day
Trial: 15134983
Drug: Bicalutamide 150
RxNorm normalized name: bicalutamide 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 150 mg once daily plus standard care
Trial: 9506661
Drug: Cholestyramine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine treatment
Trial: 26881996
Drug: Alveolar recruitment
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alveolar recruitment manoeuvres (ARM) and surfactant administration every 8 hours for 3 days
Trial: 31343761
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment only
Trial: 23316699
Drug: TAP50 (tapentadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP50 (tapentadol hydrochloride extended-release 50 mg)
Trial: 23316699
Drug: TAP250 (tapentadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP250 (tapentadol hydrochloride 250 mg)
Trial: 23316699
Drug: OXY40 (OxyContin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXY40 (OxyContin® 40 mg)
Trial: 20200310
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (2 units/h with 100 ml of 5% dextrose/h for 4 h)
Trial: 20200310
Drug: Dextrose infusion
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose infusion (100 ml of 5% dextrose/h for 4 h)
Trial: 20200310
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (100 ml of saline/h for 4 h)
Trial: 12173011
Drug: Normal whole-body
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal whole-body insulin sensitivity
Trial: 12173011
Drug: Low whole-body
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low whole-body insulin sensitivity
Trial: 7762775
Drug: Thiopentone (4-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (4-5 mg/kg) and enflurane
Trial: 7762775
Drug: Propofol (2-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2-2.5 mg/kg) infusion
Trial: 2324538
Drug: Cold-adapted influenza
RxNorm normalized name: INFLUENZA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted influenza B reassortant virus vaccine (10^7.5 TCID50)
Trial: 30962095
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine 100 μg
Trial: 30962095
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine 200 μg
Trial: 30962095
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine 100 μg (day regimen)
Trial: 30962095
Drug: C difficile
RxNorm normalized name: Clostridioides difficile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C difficile vaccine 200 μg (month regimen)
Trial: 26681191
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish (Duraphat®) plus treatment as usual
Trial: 21477658
Drug: 7-day buprenorphine
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7-day buprenorphine patches plus oral paracetamol (5-25 μg/h buprenorphine patches plus 1000 mg oral paracetamol q.i.d.; n=110)
Trial: 21477658
Drug: Co-codamol tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-codamol tablets (two 8/500-two 30/500 mg tablets q.i.d.; n=110)
Trial: 17581601
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 mg (L)
Trial: 17581601
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg (E)
Trial: 17581601
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 mg plus Enalapril 20 mg (L/E)
Trial: 10200006
Drug: Cetirizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (10 mg daily)
Trial: 12487225
Drug: Oxatomide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (1 mg/kg, twice daily)
Trial: 12487225
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg, twice daily)
Trial: 9915661
Drug: Niaspan (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaspan (extended-release niacin) at a dosage of 2,000 mg/day
Trial: 9915661
Drug: Niaspan (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niaspan (extended-release niacin)
Trial: 29127425
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (804 mg/d)
Trial: 29127425
Drug: Lipoic acid
RxNorm normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipoic acid (600 mg/d)
Trial: 27124606
Drug: Curcumin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (1000 mg/d in 2 divided doses)
Trial: 17241861
Drug: Tetomilast 25
RxNorm normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetomilast 25 mg
Trial: 17241861
Drug: Tetomilast 50
RxNorm normalized name: Tetomilast
DrugBank: Tetomilast (DB05298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetomilast 50 mg
Trial: 12081827
Drug: Etomoxir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomoxir (600 mg total over 5 doses)
Trial: 7847595
Drug: Citalopram (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (40 mg daily)
Trial: 2225476
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg p.o.)
Trial: 2225476
Drug: Pyridostigmine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine plus lipid-heparin plus GHRH
Trial: 27083315
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 0.3 mg administered preoperatively via lumbar puncture
Trial: 27083315
Drug: Diclofenac suppository
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppository (DS) 50 mg administered at the end of surgery
Trial: 21875244
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of decision advice with uncertainty estimates
Trial: 18359604
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n=78): Patients received usual customary care during weekly medical visits.
Trial: 14653835
Drug: Lafutidine 20
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lafutidine 20 mg
Trial: 9592319
Drug: Megestrol Acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol Acetate (MA) 160 mg/day orally for two weeks
Trial: 6628224
Drug: Chlorophyllin 100
RxNorm normalized name: chlorophyllin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorophyllin 100 mg/d for two weeks
Trial: 31343402
Drug: Low-dose theophylline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose theophylline (200 mg once or twice a day) for 1 year
Trial: 29520729
Drug: Velpatasvir 100
RxNorm normalized name: velpatasvir 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Velpatasvir 100 mg single dose
Trial: 19172226
Drug: Low-frequency exerciser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency exerciser (LFE) - exercise training at least 30 min twice per week or less
Trial: 17301265
Drug: Long-chain n-3
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-chain n-3 fatty acids (quartiles) among men not on aspirin
Trial: 17301265
Drug: Aspirin (randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (randomized assignment)
Trial: 7650231
Drug: Venlafaxine 75
RxNorm normalized name: venlafaxine 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 75 mg bid
Trial: 7650231
Drug: Venlafaxine 50
RxNorm normalized name: venlafaxine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 50 mg tid
Trial: 30817999
Drug: HER2-peptide vaccine
RxNorm normalized name: PEPTIDE-T
DrugBank: Peptide-T (DB19279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HER2-peptide vaccine nelipepimut-S + GM-CSF with trastuzumab
Trial: 28938963
Drug: Allogeneic human
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic human mesenchymal stem cell injection
Trial: 28938963
Drug: Standard surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard surgical care (no injection)
Trial: 24179108
Drug: Simple hand
RxNorm normalized name: ALCOHOL 75 mL in 100 mL TOPICAL LIQUID [Clean Simple Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simple hand hygiene plus antiseptic hand hygiene (water and glycerin soap for 1 minute followed by 70% ethyl alcohol gel)
Trial: 24179108
Drug: Antiseptic hand
RxNorm normalized name: MCD Antiseptic Hand
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiseptic hand hygiene (70% ethyl alcohol gel until fully dry)
Trial: 24179108
Drug: Gel-only group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel-only group (intervention)
Trial: 14717485
Drug: Healon (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healon (sodium hyaluronate) 0.05 ml injected into anterior chamber; n = 20
Trial: 14717485
Drug: Control (balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (balanced salt solution) 0.05 ml injected into anterior chamber; n = 18
Trial: 10390129
Drug: Etofibrate treatment
RxNorm normalized name: etofibrate
DrugBank: Etofibrate (DB08983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofibrate treatment for 6 weeks
Trial: 1381626
Drug: G-CSF (230
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (230 micrograms/m2 daily subcutaneous)
Trial: 1381626
Drug: Control (VAPEC-B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (VAPEC-B chemotherapy alone)
Trial: 11314884
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg amoxicillin plus 250 mg metronidazole every 8 hours for 7 days
Trial: 11314884
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets every 8 hours for 7 days
Trial: 11314884
Drug: Test group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test group (antibiotics) vs. Placebo group
Trial: 9041216
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum cardiac troponin T (cTnT) concentrations greater than 0.20 micrograms/L at baseline
Trial: 9041216
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum creatine kinase MB (CK‐MB) greater than 5.0 micrograms/L at baseline
Trial: 9041216
Drug: Increased serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased serum cardiac troponin I (cTnI) greater than 0.8 micrograms/L at baseline
Trial: 7946229
Drug: Behavioural training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioural training programme administered by nurses combining life skills training, active encouragement, and a token economy
Trial: 22448901
Drug: Anodal TDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal TDCS (2mA for 20min, 5 daily sessions)
Trial: 18079286
Drug: Citalopram (SSRI,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (SSRI, 20 mg/day)
Trial: 18079286
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg) as rescue medication
Trial: 17313004
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment for ischemic stroke (Control group)
Trial: 10972330
Drug: Allogeneic dendritic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic dendritic cells infusion
Trial: 9168216
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo tablet and saline infusion)
Trial: 1556523
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g Na2EDTA
Trial: 30197148
Drug: Kleb‐SRP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kleb‐SRP vaccine administered before calving
Trial: 30197148
Drug: Kleb‐SRP vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kleb‐SRP vaccine administered after calving
Trial: 26865592
Drug: Sf2aWC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sf2aWC vaccine (formalin‐inactivated whole‐cell Shigella flexneri 2a), given orally in three doses (2.6 ± 0.8 × 10(8), × 10(9), × 10(10), and × 10(11)vaccine particles/ml)
Trial: 26865592
Drug: Sf2aWC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sf2aWC vaccine
Trial: 24488983
Drug: Inotropic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inotropic therapy (dobutamine 43%, dopamine 24%, milrinone 17%, combination 16%)
Trial: 16255189
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of Zinacef
Trial: 10334653
Drug: Yoghurt enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoghurt enriched with Lactobacillus acidophilus L‐1
Trial: 1904120
Drug: Maintenance group
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance group received six weekly instillations of 80 mg of BCG and four additional instillations every three months.